Early initiation of glecaprevir and pibrentasvir after transplantation of HCV-viremic into HCV-uninfected kidney transplant recipients rapidly normalizes HCV-induced alterations in the soluble inflammatory milieu

Conference Reports for NATAP

The Liver Meeting
Digital Experience
AASLD
Washington on 04-08
November 2022


Early initiation of glecaprevir and pibrentasvir after transplantation of HCV-viremic into HCV-uninfected kidney transplant recipients rapidly normalizes HCV-induced alterations in the soluble inflammatory milieu

	AASLD 2022 Nov 4-8